Patents by Inventor Ramesh Krishnamoorthy
Ramesh Krishnamoorthy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11707460Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.Type: GrantFiled: August 24, 2022Date of Patent: July 25, 2023Assignee: Aerie Pharmaceuticals, Inc.Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
-
Patent number: 11590123Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.Type: GrantFiled: July 6, 2022Date of Patent: February 28, 2023Assignee: Aerie Pharmaceuticals, Inc.Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
-
Publication number: 20220409607Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.Type: ApplicationFiled: August 24, 2022Publication date: December 29, 2022Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
-
Publication number: 20220331308Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.Type: ApplicationFiled: July 6, 2022Publication date: October 20, 2022Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
-
Publication number: 20220304995Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.Type: ApplicationFiled: June 15, 2022Publication date: September 29, 2022Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
-
Patent number: 11389441Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.Type: GrantFiled: August 30, 2017Date of Patent: July 19, 2022Assignee: Aerie Pharmaceuticals, Inc.Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
-
Publication number: 20180055833Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.Type: ApplicationFiled: August 30, 2017Publication date: March 1, 2018Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
-
Publication number: 20130291860Abstract: The present invention is directed to a method for treating cystic fibrosis. The method comprises the steps of: identifying a patient suffering from cystic fibrosis, applying about 0.8-3 mL of a solution comprising about 18-65 mg/mL of denufosol into a medication reservoir of an nebulizer to achieve a target loading dose of denufosol of about 25-52 mg denufosol per dosing regimen, nebulizing the solution by passing through holes of an vibrating mesh device equipped with an oscillating membrane in the nebulizer, and delivering an inhaled respiratory dose of 20-33 mg to the lungs of the patient by inhalation within 3-9 minutes.Type: ApplicationFiled: October 6, 2011Publication date: November 7, 2013Inventors: Ramesh Krishnamoorthy, Carole Evans, Brian J. Burke, Amy E. Schaberg, Thomas G. Coady
-
Patent number: 8168597Abstract: The present invention is directed to a method for treating cystic fibrosis. The method comprises the steps of: identifying a patient suffering from cystic fibrosis, and administering to the patient an effective amount of denufosol or a pharmaceutically acceptable salt thereof and an effective amount of a macrolide. In one method, denufosol and the macrolide are administered by inhalation, preferably in a single formulation. In another method, denufosol is administered by inhalation and the macrolide is administered orally. The present invention is also directed to a pharmaceutical formulation comprising denufosol or a pharmaceutically acceptable salt thereof, a macrolide, and a pharmaceutically acceptable carrier. Preferred denufosol is denufosol tetrasodium and preferred macrolide is azithromycin. The pharmaceutical formulation preferably is in a form of an inhalable dry powder or in a liquid form.Type: GrantFiled: October 21, 2009Date of Patent: May 1, 2012Assignee: Inspire Pharmaceuticals, Inc.Inventors: Donald J. Kellerman, Ramesh Krishnamoorthy, José L. Boyer, Amy E. Schaberg
-
Publication number: 20120000941Abstract: A medicine dispenser is provided. The dispenser includes a container having a spout on a first end thereof for dispensing a medicine and defining a generally elongate base on a second end thereof. The base has a width greater than a width of the spout and further defines a sidewall having a pair of opposing sidewall portions that have generally continuous biconvex cross-sections and extend from respective wide ends of the spout and the base. The dispenser is configured for dispensing medicines of a high viscosity.Type: ApplicationFiled: June 30, 2010Publication date: January 5, 2012Applicant: INSPIRE PHARMACEUTICALS, INC.Inventors: Ramesh Krishnamoorthy, Timothy S. Hansen
-
Publication number: 20120000936Abstract: A medicine dispenser is provided. The dispenser includes a container for holding a medicine. The container has a spout on a first end for dispensing the medicine and a first cap is selectively engageable with the spout. A second cap is selectively engageable about the first end of the container and has a first major surface longitudinally spaced-apart therefrom. The first major surface extends laterally at least partially outside of a periphery of the spout to form a base for supporting the container on a proximal surface.Type: ApplicationFiled: June 30, 2010Publication date: January 5, 2012Applicant: INSPIRE PHARMACEUTICALS, INC.Inventor: Ramesh Krishnamoorthy
-
Publication number: 20100305175Abstract: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v, a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 200-400 mOsm/kG, at a pH between 4 to 8, wherein the latrunculin, the surfactant, and the tonicity agent are compatible in the formulation, and the formulation does not contain a substantial amount of dimethyl sulfoxide. The formulation is stable for at least six month at refrigerated temperature. The present invention further provides a method of reducing intraocular pressure, a method of treating glaucoma, a method of inhibiting wound healing after trabeculectomy, and a method of inhibiting angiogenesis.Type: ApplicationFiled: August 13, 2010Publication date: December 2, 2010Inventors: Ramesh Krishnamoorthy, Leo A. Trevino, Richard M. Evans
-
Patent number: 7785624Abstract: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v, a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 200-400 mOsm/kG, at a pH between 4 to 8, wherein the latrunculin, the surfactant, and the tonicity agent are compatible in the formulation, and the formulation does not contain a substantial amount of dimethyl sulfoxide. The formulation is stable for at least six month at refrigerated temperature. The present invention further provides a method of reducing intraocular pressure, a method of treating glaucoma, a method of inhibiting wound healing after trabeculectomy, and a method of inhibiting angiogenesis.Type: GrantFiled: March 1, 2007Date of Patent: August 31, 2010Assignee: Inspire Pharmaceuticals, Inc.Inventors: Ramesh Krishnamoorthy, Leo A. Trevino, Richard M. Evans, Carole Evans, legal representative
-
Publication number: 20100099635Abstract: The present invention is directed to a method for treating cystic fibrosis. The method comprises the steps of: identifying a patient suffering from cystic fibrosis, and administering to the patient an effective amount of denufosol or a pharmaceutically acceptable salt thereof and an effective amount of a macrolide. In one method, denufosol and the macrolide are administered by inhalation, preferably in a single formulation. In another method, denufosol is administered by inhalation and the macrolide is administered orally. The present invention is also directed to a pharmaceutical formulation comprising denufosol or a pharmaceutically acceptable salt thereof, a macrolide, and a pharmaceutically acceptable carrier. Preferred denufosol is denufosol tetrasodium and preferred macrolide is azithromycin. The pharmaceutical formulation preferably is in a form of an inhalable dry powder or in a liquid form.Type: ApplicationFiled: October 21, 2009Publication date: April 22, 2010Inventors: Donald J. Kellerman, Ramesh Krishnamoorthy, José L. Boyer, Amy E. Schaberg
-
Publication number: 20100003334Abstract: This invention relates to formulations for topical use comprising antibiotics in combination with anti-inflammatory steroids for treating ophthalmic infections and attendant inflammation. More specifically, this invention relates to pharmaceutical ophthalmic formulations comprising a pH stabilizing amount of tobramycin and the soft steroid loteprednol etabonate.Type: ApplicationFiled: September 1, 2009Publication date: January 7, 2010Applicant: Bausch & Lomb IncorporatedInventor: Ramesh Krishnamoorthy
-
Publication number: 20090098064Abstract: The invention provides a method for preventing or treating pulmonary edema and/or pulmonary inflammation in a subject by the administration of at least one nucleotidase. The subject is preferably a human subject. The nucleotidase is preferably of a mammalian origin, such as a human origin. The NTPDase and NPP families of nucleotidases are particularly useful for the present invention. The method reduces the bioavailability of in situ signaling extracellular nucleotides, thereby disturbing the pathological pathways in ventilator-induced lung injury (VILI) and respiratory syncytial virus infection (RSV) and other disorders such as chronic obstructive pulmonary disorder. Local administration such as inhalation is a preferred route of administration.Type: ApplicationFiled: March 16, 2007Publication date: April 16, 2009Inventors: Tomas Navratil, Kurt E. Brubaker, Jose L. Boyer, Ward M. Peterson, Ramesh Krishnamoorthy
-
Publication number: 20080194544Abstract: There is provided homogeneous pharmaceutical compositions for the treatment of, for example, rhinitis, asthma and/or chronic obstructive pulmonary disease comprising a corticosteroid and an antihistamine, a polar lipid liposome and a pharmaceutical-acceptable aqueous carrier.Type: ApplicationFiled: June 28, 2007Publication date: August 14, 2008Inventor: RAMESH KRISHNAMOORTHY
-
Patent number: 7378082Abstract: The present invention is directed to a method for treating allergic rhinitis without causing an adverse effect of bitter taste. The method comprises administering to a patient an aqueous pharmaceutical formulation comprising 0.1-0.15% (w/v) of epinastine or an acid addition salt thereof, 0.05-0.5% (w/v) of hydroxypropylmethylcellulose to maintain the viscosity between 1.5-10 centipoise, 1-2% (w/v) of propylene glycol, and a buffer to maintain the pH between 5-8, said aqueous epinastine formulation has a tonicity between 200-400 mOsm/kG; the formulation does not contain a sweetening agent. The present invention provides a method for effectively treating allergic rhinitis by delivering a small volume of the epinastine formulation to the nose of a patient using a small volume metered-dose nasal spray pump. The present method does not cause an adverse effect of bitter taste without including sweetening agents in the formulation.Type: GrantFiled: November 5, 2007Date of Patent: May 27, 2008Assignee: Inspire Pharmaceuticals, Inc.Inventor: Ramesh Krishnamoorthy
-
Publication number: 20070265247Abstract: A method and preparation for reducing dry eye symptoms and promoting tear secretion in a subject in need of such treatment is disclosed. The method is useful in treating dry eye diseases. The method is also useful in reducing contact lens intolerance in the eyes. The method comprises administering to the eyes of a subject in need thereof a non-drying antihistamine compound, such as epinastine hydrochloride, in an amount effective to reduce dry eye symptoms and stimulate tear fluid secretion. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the compound include topical administration via a liquid, gel, cream, or as part of a contact lens or a continuous or selective release device; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form, injectable, intra-operative instillation or suppository form.Type: ApplicationFiled: June 21, 2007Publication date: November 15, 2007Inventors: Benjamin Yerxa, Jason Vittitow, John Ice, Ramesh Krishnamoorthy
-
Patent number: D640554Type: GrantFiled: June 30, 2010Date of Patent: June 28, 2011Inventor: Ramesh Krishnamoorthy